August 22, 2013
Plandaí Shares Hit New Year High Despite Market Slump
Shares of Plandaí Biotechnology Inc. (OTCQB – PLPL - $0.66 – Spec Buy) closed at a new 52-week high yesterday, despite the current stock market slump. The shares may be further bolstered by results of a research study conducted by The Coca-Cola Company (NYSE – KO) that indicate drinking polyphenol rich juice may have benefits associated with a positive change in a major protein that affects arterial health. These findings should be viewed as a positive event and as corroborating third-party evidence from the world’s leading beverage producer and thus a boon to Plandaí. The Company plans to introduce highly bioavailable extract products under the Company’s Phytofare™ line that specifically contain these polyphenols which can be used in juices and other beverages.
Polyphenols are derived from natural extracts and have been the subject of extensive research due to their high antioxidant activity and a demonstrated capability to eliminate free radicals, or polluted cells. They are commonly found in green tea extracts, or green tea gallate catechin extracts, and carotenoid botanical extracts found in tomatoes and other ‘colorful’ vegetables.
The aforementioned study was conducted in a partnership with the University of Glasgow and Mosaiques Diagnostics, GmbH. Results demonstrated that the levels of 27 polypeptides, which are protein or amino acid chains in the arteries and elsewhere, increased by nearly 4 times in experimental candidates that consumed the polyphenol rich juices over time. Seven of the 27 polypeptides are known urinary markers for coronary artery disease. Researchers stated that the seven coronary artery disease markers moved closer to a ‘healthy state’ for those candidates who consumed the polyphenol-rich juices. The bottom line is that the study demonstrated that drinking green tea extract or carotenoid extract appears to improve arterial function at the molecular level.
To that end, Plandaí’s Phytofare™ Catechin Complex and Carotenoid Complex have been formulated with a proprietary process that will enable the release of more of these polyphenol compounds versus the competitors. This product differentiation is created with superior bioavailability, or the measurement of an amount of a compound that is absorbed into the bloodstream. Normal extracts produce 1-10% bioavailability, while the Phytofare™ extract products have demonstrated 70% on average for bioavailability.
Plandaí is on target to begin production of the Phytofare™ Catechin Complex in powder form, topical cream, gel tabs, and a liquid by the end of 1Q14. The liquid form can be used in beverages while the other forms can be incorporated into various supplements and nutriceuticals offering a host of superior health benefits including those discussed in the example above. Additionally, the Company has partnered with several distributors in the U.S., Europe and Africa to sell market and distribute Plandai's Phytofare™ extracts in 1Q14 as well.
Plandaí’s aggressive marketing campaign will reap major benefits from the message that beverages and other products that utilize the Phytofare™ products can provide superior levels of healthy ingredients, such as the polyphenols mentioned above. This differentiation should help the Company expand its market share and generate strong results in 2014.
For more information, refer to our previous PLPL Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com
You Might Also Like
Senior Analyst: Robert Goldman
This article is the opinion of Goldman Small Cap Research and was written based upon publicly available information. The Company has not endorsed or compensated Goldman Small Cap Research for this article. All information contained in this report was provided by the Company or derived from GSCR due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.